Adamis Pharmaceuticals

Adamis Pharmaceuticals is a speciality biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.In May 2023, Adamis Pharmaceuticals Corp announced the closing of its merger with DMK Pharmaceuticals Inc.In August 2021, Adamis Pharmaceuticals Corporation announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc.In March 2016, Adamis entered into a definitive merger agreement to acquire all outstanding shares of US Compounding Inc for approximately 1.62 million shares of Adamis common stock, and Adamis would assume certain secured debt obligations. At that time, the transaction was expected to close in the second quarter of 2016. In April 2016, the acquisition was completed and US Compounding became a wholly-owned subsidiary of Adamis.In December 2009, La Jo